Lindsey Wang, from Case Western Reserve University School of Medicine in Cleveland, and colleagues compared the incident risk for each of 13 OACs in patients with T2D prescribed GLP-1 RAs versus insulins or metformin in a retrospective cohort study. The study population included 1,651,452 patients with T2D with no prior diagnosis of OACs.
"The potential cancer-preventative effects of OACs by GLP-1 RAs warrant further long-term studies as well as studies of individual newer and possibly more effective antidiabetic and weight loss agents as well as those with multihormone agonist activities," the authors write.
Abstract/Full Text
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.